CN103260622B - 作为酪蛋白激酶抑制剂的新型稠合吡啶化合物 - Google Patents
作为酪蛋白激酶抑制剂的新型稠合吡啶化合物 Download PDFInfo
- Publication number
- CN103260622B CN103260622B CN201180061257.2A CN201180061257A CN103260622B CN 103260622 B CN103260622 B CN 103260622B CN 201180061257 A CN201180061257 A CN 201180061257A CN 103260622 B CN103260622 B CN 103260622B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- fluorophenyl
- base
- pyrazoles
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CS(N1Cc2ncccc2C1)#* Chemical compound CS(N1Cc2ncccc2C1)#* 0.000 description 2
- SJMNQXLXIIXDDS-UHFFFAOYSA-N C1NCc2ncccc12 Chemical compound C1NCc2ncccc12 SJMNQXLXIIXDDS-UHFFFAOYSA-N 0.000 description 1
- CHJATJOPJJJZOI-UHFFFAOYSA-N C=CCC(CCc(ccnc12)c1OCCNC2=O)F Chemical compound C=CCC(CCc(ccnc12)c1OCCNC2=O)F CHJATJOPJJJZOI-UHFFFAOYSA-N 0.000 description 1
- PLCVKAVTFWZPGX-UHFFFAOYSA-N CC(C)(C)OC(NCCOc(c(C#N)ncc1)c1-c1c[n](C)nc1-c(cc1)ccc1F)=O Chemical compound CC(C)(C)OC(NCCOc(c(C#N)ncc1)c1-c1c[n](C)nc1-c(cc1)ccc1F)=O PLCVKAVTFWZPGX-UHFFFAOYSA-N 0.000 description 1
- CEQOXKHWSBSYSD-UHFFFAOYSA-N CC(CCc(ccnc1C#N)c1OCCN)F Chemical compound CC(CCc(ccnc1C#N)c1OCCN)F CEQOXKHWSBSYSD-UHFFFAOYSA-N 0.000 description 1
- JFJCHGRUMLXVNI-UHFFFAOYSA-N C[n](cc1-c(ccnc2C#N)c2F)nc1-c(cc1)ccc1F Chemical compound C[n](cc1-c(ccnc2C#N)c2F)nc1-c(cc1)ccc1F JFJCHGRUMLXVNI-UHFFFAOYSA-N 0.000 description 1
- CPPZTHBOBZRSTN-UHFFFAOYSA-N C[n](cc1-c(ccnc2C(N3Cc4ccccc4)=O)c2C3=O)nc1-c(cc1)ccc1F Chemical compound C[n](cc1-c(ccnc2C(N3Cc4ccccc4)=O)c2C3=O)nc1-c(cc1)ccc1F CPPZTHBOBZRSTN-UHFFFAOYSA-N 0.000 description 1
- FLOCRZOELBFREL-UHFFFAOYSA-N C[n](cc1-c(ccnc2CN3Cc4ccccc4)c2C3=O)nc1-c(cc1)ccc1F Chemical compound C[n](cc1-c(ccnc2CN3Cc4ccccc4)c2C3=O)nc1-c(cc1)ccc1F FLOCRZOELBFREL-UHFFFAOYSA-N 0.000 description 1
- RDUXJEGWTNOYDA-UHFFFAOYSA-N C[n](cc1-c2c3OCCNCc3ncc2)nc1-c(cc1)ccc1F Chemical compound C[n](cc1-c2c3OCCNCc3ncc2)nc1-c(cc1)ccc1F RDUXJEGWTNOYDA-UHFFFAOYSA-N 0.000 description 1
- CHSFPCMJLAXYGH-UHFFFAOYSA-N C[n](cc1-c2ccnc(C(O3)=O)c2C3=O)nc1-c(cc1)ccc1F Chemical compound C[n](cc1-c2ccnc(C(O3)=O)c2C3=O)nc1-c(cc1)ccc1F CHSFPCMJLAXYGH-UHFFFAOYSA-N 0.000 description 1
- ZHXBMFZMAKZAJI-UHFFFAOYSA-N C[n](cc1-c2ccnc(C3)c2CN3S=O)nc1-c(cc1)ccc1F Chemical compound C[n](cc1-c2ccnc(C3)c2CN3S=O)nc1-c(cc1)ccc1F ZHXBMFZMAKZAJI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061425213P | 2010-12-20 | 2010-12-20 | |
| US61/425,213 | 2010-12-20 | ||
| PCT/IB2011/055489 WO2012085721A1 (en) | 2010-12-20 | 2011-12-06 | Novel fused pyridine compounds as casein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103260622A CN103260622A (zh) | 2013-08-21 |
| CN103260622B true CN103260622B (zh) | 2015-05-13 |
Family
ID=45446116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180061257.2A Active CN103260622B (zh) | 2010-12-20 | 2011-12-06 | 作为酪蛋白激酶抑制剂的新型稠合吡啶化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8536164B2 (enExample) |
| EP (2) | EP2654750B1 (enExample) |
| JP (2) | JP5684923B2 (enExample) |
| KR (1) | KR101590236B1 (enExample) |
| CN (1) | CN103260622B (enExample) |
| AR (1) | AR084412A1 (enExample) |
| AU (1) | AU2011346733C1 (enExample) |
| CA (1) | CA2819961C (enExample) |
| CY (2) | CY1118772T1 (enExample) |
| DK (2) | DK3181133T3 (enExample) |
| ES (2) | ES2744099T3 (enExample) |
| HR (2) | HRP20170484T1 (enExample) |
| HU (2) | HUE047089T2 (enExample) |
| IL (1) | IL226948A (enExample) |
| LT (2) | LT3181133T (enExample) |
| MX (1) | MX338551B (enExample) |
| PL (2) | PL3181133T3 (enExample) |
| PT (2) | PT2654750T (enExample) |
| RS (2) | RS55897B1 (enExample) |
| SG (1) | SG190802A1 (enExample) |
| SI (2) | SI3181133T1 (enExample) |
| WO (1) | WO2012085721A1 (enExample) |
| ZA (1) | ZA201303453B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012004997A (es) * | 2009-10-28 | 2012-06-12 | Pfizer | Derivados de imidazol como inhibidores de la caseina quinasa. |
| US9938269B2 (en) * | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| CN104837844B (zh) * | 2012-12-21 | 2017-08-29 | 百时美施贵宝公司 | 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 |
| WO2015163446A1 (ja) * | 2014-04-25 | 2015-10-29 | 協和発酵キリン株式会社 | イミダゾール化合物の製造方法 |
| JP2017222576A (ja) * | 2014-10-31 | 2017-12-21 | 石原産業株式会社 | 有害生物防除剤 |
| CN107365315B (zh) * | 2016-05-11 | 2024-08-09 | 国药集团国瑞药业有限公司 | 一种吡唑类化合物、其晶型及其制备方法 |
| US10973820B2 (en) * | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
| TW202112368A (zh) * | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| CN115335057A (zh) * | 2020-03-27 | 2022-11-11 | 北京原基华毅生物科技有限公司 | 抑制酪蛋白激酶的方法 |
| US20230192699A1 (en) * | 2020-03-27 | 2023-06-22 | Gritscience Biopharmaceuticals Co., Ltd. | Compounds as casein kinase inhibitors |
| AR122711A1 (es) | 2020-06-25 | 2022-09-28 | Alchemedicine Inc | COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA |
| CN111808102B (zh) * | 2020-08-03 | 2021-12-31 | 南通大学 | 一种3-甲氧基-6,7-二氢-5H-吡咯并[3,4-b]吡啶盐酸盐及其合成方法 |
| AU2021345564A1 (en) * | 2020-09-17 | 2023-06-01 | Janssen Pharmaceutica Nv | Casein kinase 1 delta modulators |
| US20230339970A1 (en) * | 2020-09-17 | 2023-10-26 | Janssen Pharmaceutica Nv | Casein kinase 1 delta modulators |
| US20240076291A1 (en) * | 2020-11-24 | 2024-03-07 | Merck Sharp & Dohme Llc | Modified isoindolinones as glucosylceramide synthase inhibitors |
| CN116888126B (zh) * | 2020-12-15 | 2026-03-17 | 北京原基华毅生物科技有限公司 | 一种酪蛋白激酶抑制剂的化合物 |
| US20230053307A1 (en) * | 2021-07-19 | 2023-02-16 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating skin disorders and conditions |
| WO2023241552A1 (en) * | 2022-06-14 | 2023-12-21 | Gritscience Biopharmaceuticals Co., Ltd | Salt and/or crystal form for compounds as casein kinase inhibitors |
| CN117362303B (zh) * | 2022-07-02 | 2026-02-03 | 黑龙江联顺生物科技有限公司 | 一种生物素中间体环酐的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0151962A3 (en) | 1984-01-25 | 1985-10-02 | Beecham Group Plc | Pyrazolopyridine derivatives |
| HUP0001880A3 (en) * | 1997-05-22 | 2002-03-28 | G D Searle & Co Chicago | Substituted pyrazoles as p38 kinase inhibitors |
| AU2728201A (en) * | 1999-12-21 | 2001-07-03 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| MX2007015917A (es) | 2005-06-22 | 2008-03-10 | Chemocentryx Inc | Compuestos de azaindazol y metodos de uso. |
| WO2007140213A1 (en) | 2006-05-26 | 2007-12-06 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
| EP2308866A1 (de) * | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
| MX2012004997A (es) * | 2009-10-28 | 2012-06-12 | Pfizer | Derivados de imidazol como inhibidores de la caseina quinasa. |
-
2011
- 2011-12-06 WO PCT/IB2011/055489 patent/WO2012085721A1/en not_active Ceased
- 2011-12-06 AU AU2011346733A patent/AU2011346733C1/en not_active Ceased
- 2011-12-06 LT LTEP17151228.8T patent/LT3181133T/lt unknown
- 2011-12-06 KR KR1020137015822A patent/KR101590236B1/ko not_active Expired - Fee Related
- 2011-12-06 DK DK17151228.8T patent/DK3181133T3/da active
- 2011-12-06 RS RS20170387A patent/RS55897B1/sr unknown
- 2011-12-06 HU HUE17151228A patent/HUE047089T2/hu unknown
- 2011-12-06 SI SI201131784T patent/SI3181133T1/sl unknown
- 2011-12-06 LT LTEP11805210.9T patent/LT2654750T/lt unknown
- 2011-12-06 CN CN201180061257.2A patent/CN103260622B/zh active Active
- 2011-12-06 EP EP11805210.9A patent/EP2654750B1/en active Active
- 2011-12-06 EP EP17151228.8A patent/EP3181133B1/en active Active
- 2011-12-06 HU HUE11805210A patent/HUE032405T2/en unknown
- 2011-12-06 PT PT118052109T patent/PT2654750T/pt unknown
- 2011-12-06 SI SI201131141A patent/SI2654750T1/sl unknown
- 2011-12-06 JP JP2013545540A patent/JP5684923B2/ja active Active
- 2011-12-06 SG SG2013036934A patent/SG190802A1/en unknown
- 2011-12-06 CA CA2819961A patent/CA2819961C/en active Active
- 2011-12-06 PL PL17151228T patent/PL3181133T3/pl unknown
- 2011-12-06 ES ES17151228T patent/ES2744099T3/es active Active
- 2011-12-06 HR HRP20170484TT patent/HRP20170484T1/hr unknown
- 2011-12-06 RS RS20191036A patent/RS59098B1/sr unknown
- 2011-12-06 PL PL11805210T patent/PL2654750T3/pl unknown
- 2011-12-06 ES ES11805210.9T patent/ES2623387T3/es active Active
- 2011-12-06 PT PT17151228T patent/PT3181133T/pt unknown
- 2011-12-06 DK DK11805210.9T patent/DK2654750T3/en active
- 2011-12-06 MX MX2013005833A patent/MX338551B/es active IP Right Grant
- 2011-12-13 US US13/323,883 patent/US8536164B2/en active Active
- 2011-12-19 AR ARP110104787A patent/AR084412A1/es not_active Application Discontinuation
-
2013
- 2013-05-13 ZA ZA2013/03453A patent/ZA201303453B/en unknown
- 2013-06-13 IL IL226948A patent/IL226948A/en active IP Right Grant
-
2015
- 2015-01-14 JP JP2015005142A patent/JP5876596B2/ja active Active
-
2017
- 2017-03-27 CY CY20171100378T patent/CY1118772T1/el unknown
-
2019
- 2019-08-14 HR HRP20191469 patent/HRP20191469T1/hr unknown
- 2019-08-21 CY CY20191100892T patent/CY1122062T1/el unknown
Non-Patent Citations (1)
| Title |
|---|
| entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes;Meng QING-JUN 等;《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA》;20100831;第107卷(第34期);15240-15245 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103260622B (zh) | 作为酪蛋白激酶抑制剂的新型稠合吡啶化合物 | |
| CA2821712C (en) | Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors | |
| AU2017288755B2 (en) | Novel compound or pharmaceutically acceptable salt thereof | |
| KR102300612B1 (ko) | 피리디닐 및 융합 피리디닐 트리아졸론 유도체 | |
| KR101821903B1 (ko) | 헤테로바이사이클로아릴 rorc2 억제제 및 이의 사용 방법 | |
| CA3092770A1 (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
| CA3005658A1 (en) | Modulators of ror-gamma | |
| IL194832A (en) | History of pyridopyrazine and pharmaceutical preparations | |
| CN101965347B (zh) | 作为激酶抑制剂的吡唑并吡啶 | |
| CN103228660A (zh) | Kat ii 抑制剂 | |
| WO2009089352A1 (en) | Pyrrolopyridines as kinase inhibitors | |
| AU2012261077B2 (en) | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors | |
| HK1188145B (en) | Novel fused pyridine compounds as casein kinase inhibitors | |
| HK1187612A (en) | Kat ii inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1188145 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1188145 Country of ref document: HK |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201204 Address after: Massachusetts USA Patentee after: Biogen Idec MA Inc. Address before: New York State, USA Patentee before: Pfizer Inc. |